Complete Lung Cancer Drugs List (2026 Update)
Lung cancer remains the leading cause of cancer death worldwide, with non-small cell lung cancer…
News
Adamgammadex Sodium Approved by NMPA: The World’s Second and China’s First Homegrown Targeted Neuromuscular Block Reversal Agent
On July 1, China’s National Medical Products Administration (NMPA) approved Adamgammadex Sodium Injection for marketing.…
ALK Inhibitors for Lung Cancer: Generational Evolution and Impact on Clinical Practice
Before the advent of targeted therapy, ALK-positive advanced non-small cell lung cancer (NSCLC) typically progressed…
Octahydroaminoacridine Succinate Approved in China for Alzheimer’s Disease, Marking Progress in Innovative Drug Development
On June 25, 2026, the National Medical Products Administration (NMPA) announced Octahydroaminoacridine Succinate approved in…
What Ovarian Cancer Drugs Are Available in China? Drug List and Clinical Uses
Ovarian cancer drugs in China mainly include five categories: PARP inhibitors, anti-angiogenic therapies, antibody-drug conjugates…
From First- to Third-Generation EGFR-targeted Drugs: How Can Patients Understand Differences in Efficacy and Adverse Effects?
Epidermal growth factor receptor EGFR–targeted drugs represent a cornerstone in the treatment of advanced non–small…
Pharmaceutical Distributor in Hong Kong | Licensed Wholesale & Drug Export Partner
DengYueMed is a licensed Pharmaceutical Distributor in Hong Kong providing wholesale pharmaceuticals, global drug export,…
What Are the Treatment Options for Duchenne Muscular Dystrophy? Current Therapies, Gene Therapy, and Emerging Treatments
What are the treatment options for Duchenne muscular dystrophy? Current treatment options for Duchenne muscular…
China National Essential Medicines List 2026: Key Updates on Innovative Drugs, GLP-1 and Cancer Therapies
On July 9, 2026, China officially released the China National Essential Medicines List 2026, adding…
How to Find the Latest Breast Cancer Drugs: 7 Trusted Steps
How to find the latest breast cancer drugs begins with knowing your breast cancer subtype…